Ruemu Birhiray, MD
Hematology & Oncology · Indianapolis, INNPI 1295735058
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,219,733 of the $3,055,048 with a category attached, or 72.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 14.1%. Among hematology & oncology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,567 payments — averaging $856.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$429K
- Incyte Corporation$416K
- AstraZeneca$247K
- Amgen$230K
- Lilly USA, LLC$195K
- Puma Biotechnology, Inc.$160K
- plus $1.4M from 54 others
Across 225 payments — averaging $3996.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$268K
- Novartis$197K
- Regeneron$174K
- Genentech, Inc.$109K
- Boehringer Ingelheim$103K
- Incyte Corporation$18K
- plus $30K from 5 others
What the payments were for
- Consulting fees$340,19811%
- Speaking & faculty fees$2,219,73373%
- Travel & lodging$417,59314%
- Food & beverage$75,2582%
- Education$9680%
- Other$1,2980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,055,048 in reported general payments places this provider in the 95th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 143 | $2,105,854 |
| RevlimidLenalidomide | 95 | $1,528,836 |
| ImbruvicaIbrutinib | 52 | $916,635 |
| BrukinsaZanubrutinib | 40 | $485,089 |
| CabometyxCabozantinib S-Malate | 14 | $348,468 |
| OnuregAzacitidine | 13 | $332,698 |
| JakafiRuxolitinib Phosphate | 19 | $321,069 |
| PomalystPomalidomide | 13 | $292,240 |
| NinlaroIxazomib Citrate | 22 | $281,926 |
| OrserduElacestrant Hcl | 11 | $254,905 |
| XtandiEnzalutamide | 16 | $231,383 |
| BosulifBosutinib | 16 | $208,692 |
| VenclextaVenetoclax | 22 | $199,314 |
| Lenalidomide | 13 | $193,718 |
| IbrancePalbociclib | 11 | $174,769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $194,571 | $2,105,854143 claims |
| Bristol Myers SquibbRevlimid | $3,963 | $1,528,83695 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $130,700 | $916,63552 claims |
| E.r. Squibb & Sons, L.L.C.Onureg, Pomalyst | $85,019 | $624,93826 claims |
| Beigene USA, Inc.Brukinsa | $76,010 | $485,08940 claims |
| PfizerBosulif, Ibrance, Eliquis, Trazimera | $10,980 | $468,606112 claims |
| Exelixis Inc.Cabometyx | $86,560 | $348,46814 claims |
| Incyte CorporationJakafi | $416,218 | $321,06919 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $9,730 | $281,92622 claims |
| Stemline Therapeutics Inc.Orserdu | $65,549 | $254,90511 claims |
| Astellas Pharma US IncXtandi | $19,114 | $231,38316 claims |
| AbbVieVenclexta | $67,839 | $199,31422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Indianapolis
- Richard GaynorIndianapolis$3.7M
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
- Daniel MiltonIndianapolis$231K
- Amro ElshouryIndianapolis$212K
- Brian MulherinIndianapolis$175K
- Muhammad Sarfraz NawazIndianapolis$172K
- John EdwardsIndianapolis$169K
- Karam Al-IssaIndianapolis$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.